Emergent Biosolutions: Q3 Earnings Snapshot

Emergent Biosolutions reported a Q3 loss of $32.7M, or 64 cents per share, with adjusted losses of 36 cents per share. Revenue was $110M. The company expects full-year revenue between $600M and $645M, according to its earnings release.

Original reporting
Published Nov 3, 2026, 4:25 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 4:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Emergent Biosolutions: Q3 Earnings Snapshot — source image
Decision brief

The 30-second read

$EBSBearishMed
01

Why it matters

The Q3 earnings miss may trigger a sell‑off, but investors may watch for upcoming data releases that could change sentiment.

02

Market read

First‑time earnings disclosure for EBS with negative results; relevant for biotech traders.

03

What to watch

Potential pipeline developments or upcoming contract wins not disclosed in this brief could offset the earnings weakness.

Relevance 7/10Novelty 8/10Timing: after‑hours release

Background

Emergent Biosolutions (EBS) is a U.S. biopharmaceutical company focused on specialty vaccines and therapeutics.

Company-level read

Ticker impact

$EBSBearishHigh confidence
Context

Emergent Biosolutions reported a Q3 loss of $32.7M, revenue of $110M and full‑year revenue guidance of $600M‑$645M.

Expected impact

likely downward pressure as the market prices in the loss and lower guidance

Evidence & confidence

Loss of 64¢ per share and guidance below prior expectations typically trigger sell‑offs in biotech stocks.

Market effects

Biopharma sector may see modest weakness as earnings miss highlights broader industry risk.

U.S. biotech investors could adjust exposure in the short term.

Limited to investors tracking U.S. biotech earnings; no broader macro effect.

Counterpoint

If the loss is viewed as a one‑time charge, the stock could rebound on a short‑term oversell.

Key entities

  • Emergent Biosolutions

    U.S. biopharma reporting Q3 results.

Related articles

$EBSMedAI 8/10

Emergent BioSolutions Inc (EBS) (Q3 2026) Earnings Call Highlights: Revenue Timing Weighs

Emergent BioSolutions reported Q3 2026 revenue of $110M, down from $231M in Q3 2025 due to MCM delivery timing. Adjusted EBITDA was -$5M, with adjusted gross margin at 28%. Full-year 2026 revenue guidance was updated to $600M-$645M. The company faces competitive pricing pressure in the naloxone market and expects MCM revenues to decline. CFO Richard Lindahl is retiring, and net leverage remained stable at 2.4 times.

$EBSMedAI 8/10

Emergent BioSolutions 2026: Revenue $110M, EPS ($0.64) — 10-Q Summary

Emergent BioSolutions reported Q3 2026 revenue of $110M, a 52.4% YoY decline, and a net loss of $32.7M, compared to a profit of $51.2M a year earlier. Nine-month revenue fell 16% to $500.4M, driven by lower NARCAN sales and declines in medical countermeasure products. The company reduced its workforce by 90 employees in August to cut costs.

$EBSMed

Emergent BioSolutions (EBS) Q3 2026 Earnings Call Transcript

Emergent BioSolutions reported Q3 2026 revenue of $110M, within guidance, bringing YTD revenue to $500M. Adjusted EBITDA reached $128M (25% margin), with $122M in operating cash flow. The company highlighted progress in its transformation plan, including contract modifications and international sales. CFO Rich Lindahl announced his retirement, with Frank Vargo assuming the role in 2027. The company also discussed its role in biodefense and AI partnerships for clinical development.

$EBSMed

Emergent Biosolutions Q3 Earnings Call Highlights

Emergent Biosolutions reported Q3 cash of $176M, reduced gross debt by $179M YoY, and repurchased $75M in bonds. MCM revenue was $59M, with international sales contributing $72M. Naloxone market faced competition. 2026 revenue guidance updated to $600M-$645M. CFO to retire, interim replacement named. (EBS)

$EBSMed

EMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS

Emergent BioSolutions Inc. (EBS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS • Third Quarter 2026 Total Revenues of $110.0 million • Third Quarter 2026 Net Loss of $32.7 million and Net Loss Margin was (30)% • Third Quarter 2026 Adjusted Net Loss of $18.7 million • Third Quarter 2026 Gross